Trichophytosis of the skin is one of the most common diseases of outpatients encountered, and various external remedies have been tried for its treatment. In spite of proper use of these remedies, however recurrence as a result of incomplete cure, development of dermatitis caused by irritation of the remedy used, and unsuccessful topical treatment because of deep-seated lesion have been observed in many cases. Therefore, clinicians are anxious for the appearance of oral remedy, difinitely effective and without the above mentioned defects.

Griseofulvin, an antibiotic firstly isolated from Penicilliurn griseofulvurn Dierckx by Rainstrick, Simonart and Oxford, in 1939, is just the remedy that meets those demand. The recent reports from Europe and the United States described the favorable effects of griseofulvin in both experimental and clinical dermatomycoses. The authors recently had a chance to try griseofulvin tablets for clinical dermatomycosis, being supplied with samples by the courtesy of Glaxo Laboratories Ltd. and Shin Nihon Jitsugyo Co. Ltd. Although the term of observation is short to draw final conclusion, the results obtained to this day are presented here.